We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genome Researchers Identify Mutation Linked to Cardiac Disorder

By LabMedica International staff writers
Posted on 22 Mar 2017
An international team of genome researchers has identified a gene variant linked to the potentially lethal cardiac disorder ARVC (Arrhythmogenic right ventricular cardiomyopathy). More...


ARVC is a life-threatening disease that often afflicts (although is not exclusive to) young male athletes. Mutations within the desmosome - molecular complexes of cell adhesion proteins and linking proteins that attach the cell surface adhesion proteins to intracellular keratin cytoskeletal filaments - are the main cause of ARVC. The mutations cause the replacement of heart muscle by fatty and fibrous tissue. This process encourages the development of cardiac arrhythmias such as tachycardia and ventricular fibrillation, which cause loss of consciousness and cardiac arrest. The current incidence within the population is accepted as 1/10,000 however it is thought that 1/200 may have a mutation that may predispose to ARVC.

Investigators from Canada, South Africa, and Italy collaborated to perform a whole exome sequencing study on two cousins from a South African family affected by ARVC that had experienced several cases of juvenile sudden death over a period of 20 years. After eliminating more than 13,000 common genetic variants, a mutation in the gene cadherin 2 (CDH2), was identified in the two cousins.

CDH2, also called N-cadherin, named originally for its role in neural tissue, was later was found to be active in cardiac muscle and in cancer metastasis. CDH2 is a transmembrane, homophilic glycoprotein belonging to the calcium-dependent cell adhesion molecule family. These proteins have extracellular domains that mediate homophilic interactions between adjacent cells, and C-terminal, cytoplasmic tails that mediate binding to catenins, which in turn interact with the actin cytoskeleton.

"This is important news for families who have had a young family member suffer a sudden cardiac death, for them to know a genetic cause has been identified," said contributing author Dr. Guillaume Paré, associate professor of pathology and molecular medicine at McMaster University.

"Our team was happy to contribute to the finding that a mutation in CDH2 is the underlying culprit in a portion of these patients. This will pave the way for preventative interventions and genetic counselling."

The study was published in the March 8, 2017, online edition of the journal Circulation: Cardiovascular Genetics.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.